Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Sumitomo Pharma Oncology, Inc.
About
  2. Companies
  3. Sumitomo Pharma Oncology, Inc.
  4. Products
  5. Sumitomo - Model DSP-7888 - ...

Sumitomo - Model DSP-7888 - Ombipepimut-S Emulsion WT1 Immunotherapeutic Cancer Vaccine

SHARE

Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic malignancies and solid tumors.1,2 Researchers have identified that adding helper T-cell–inducing peptides improved WT1-specific CTL induction, which may contribute to tumor cytotoxicity.1

Most popular related searches
cancer vaccine
T-cell
solid tumor
vaccination
ovarian cancer
brain tissue
hematologic malignancies
clinical study
clinical trial
cancer cell

Understanding the target
The WT1 antigen may be a promising target for immunotherapy, as its expression correlates with poor prognosis and tumorigenicity in glioblastoma multiforme (GBM) while being functionally absent in normal brain tissue.3-8 Additionally, WT1 is expressed across a range of cancer types and plays a key role in cell proliferation, differentiation, and the apoptotic process.4,9,10

Clinical evidence
In early-phase clinical trials, Ombipepimut-S Dosing Emulsion was shown to induce and prompt WT1-CTL activation in patients with advanced malignancies.11

Ongoing development
Ombipepimut-S Dosing Emulsion is currently being investigated in a series of combination therapy clinical studies, including a phase III trial for recurrent or progressive glioblastoma and a phase I/II trial for advanced solid tumors (phase 1B) and platinum-resistant ovarian cancer (phase II).